Clinical Trials

Introduction to Clinical Trials

This is a selection of our current Clinical Trials.

Avanir Study - AVP 786

Treatment of Agitation in patients with Alzheimer's Disease
12 week treatment study.

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/ quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type.

Inclusion

Exclusion

  • Moderate/severe agitation
  • Age 50-90
  • MMSE 6-26
  • Patients will need a study partner   / caregiver
  • Dose stable on AD medication for min 3 months
  • Patients with symptoms of agitation that are not secondary to AD
  • Participation in other drug trials within 30 days of baseline
Contact us for further information

Cookies on our website

Cookies are used to ensure you get the best browsing experience. No personally identifiable information is collected.
By using our site you agree to these cookies being used. For more information please see our Cookie Policy.